Clinical effectiveness of low-dose chlorthalidone (6.25 mg) + atenolol combination in stage I hypertensive patients: A multicenter, randomized, controlled study

Current Medical Research and Opinion

Volumn 24, Issue 6, 2008, Pages 1771-1779

  Pareek, Anil ^a   Karnik, N ^b   Salagre, S B ^c   Zawar, S D ^d   Joglekar, V K ^e   Chandurkar, N ^a   Naik, G S ^a  

^a Ipca Laboratories Ltd   (India)

^b LOKMANYA TILAK MUNICIPAL GENERAL HOSPITAL   (India)

^c KEM HOSPITAL   (India)

^d GOVERNMENT MEDICAL COLLEGE   (India)

^e GRANT MEDICAL COLLEGE   (India)

Author keywords

Amlodipine; Atenolol; Chlorthalidone; Stage I essential hypertension

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS ATENOLOL; ANTIHYPERTENSIVE AGENT; ATENOLOL; CHLORTALIDONE;

ADULT; AGED; AGEUSIA; ANOREXIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BRADYCARDIA; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA AND VOMITING; NECK PAIN; PARESTHESIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN TINGLING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CHLORTHALIDONE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 46449109948     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802118071     Document Type: Article

References (20)

1. Scholze J, Bida M, Hansen A, et al. Initiation of hypertension treatment with a fixed dose combination or its monocomponents - Does it really matter? Int J Clinical Pract 2006;60:265-74
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. JAMA 2002;288:2981-97
3. Wright JT, Dunn JK, Cutler JA, et al. For the ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293:1595-608
4. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-44
5. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA 1979;242:2562-71
6. The Multiple Risk Factor Intervention Trial Research Group (MRFIT). Mortality rates after 10.5 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation 1990;82:1616-28
7. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64
8. Neaton JD, Grimm RH, Prineas RJ, et al. For the Treatment of Mild Hypertension Study Research Group. Treatment of mild hypertension study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993;270:713-24
9. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The seventh report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). JAMA 2003;289:2560-72
10. Barry LC, Michael EE, Jerome DC. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
11. Barry LC, Chris JG, Jennifer JG, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-8
12. Ruzicka M, Leenen FH. Combination therapy as firstline treatment of arterial hypertension. Can J Cardiol 2002;18:1317-27
13. Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002;4:393-404
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998;26:S80-2
15. Black HR, Elliot WJ, Grandits G, et al. Principal results of the Controlled Onset Verapramil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82
16. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertensive Study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003
17. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993;328:914-21
18. 2003 European Society of Hypertension - European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
19. Zidek W. Hochdruckleitlinien iiberabeitet. Was ist Praxisrelevant? MMW Fortschr Med 2004;1-2:16/37-8/17
20. Curry RC Jr Schwartz KM, Urban PL. Atenolol and chlorthalidone therapy for hypertension: a double blind comparison. South Med J 1988;81:1401-6, 1411